The US Department of Health and Human Services (HHS) announced on Thursday that a new rule allowing prescription drug companies to charge more for drugs they don’t actually need is being rolled out in a pilot program.
The new rules are meant to ensure that patients have access to quality drugs.
But some people are already wondering how much prescription drug prices will go up if the new rules take effect.
Read more from Recode: A new rule that could cost more for some Americans’ prescription drugs could cause some to skip their appointments, and it’s all thanks to a glitch in the federal system.
The Centers for Medicare & Medicaid Services (CMS) announced that it will be rolling out a new set of rules on Thursday aimed at ensuring patients have affordable and quality prescription drugs, including those in its own networks.
These rules are the first step in a process to roll out a pilot study of a new prescription drug pricing system in the United States.
But they’re just the beginning of a long-term process that is expected to cost consumers $2.7 trillion over the next decade.
“The cost of a prescription drug is going to go up, and that’s because the industry is going through a major transformation and is trying to figure out a way to provide access to high-quality medicines that have value,” said CMS Commissioner David Shulkin in a press conference on Thursday.
“We’re going to need to figure it out.”
The new pricing system is the first phase of a plan by the agency to phase out its current prescription drug program, which has been criticized for overcharging for some medicines.
For example, the new system will not allow the FDA to make an estimate of how much it costs to buy a generic drug, which is typically the most cost-effective option.
The agency also will no longer allow the agency that provides the drugs to charge a percentage of the cost of the drug.
As part of the pilot, patients will be able to pay for a specific set of prescription drugs with their premiums.
But the new pricing rules do not address whether the government should be able or willing to provide subsidies to companies to cover some of the costs.
This is the second time the government has attempted to roll back its prescription drug costs.
The first time was in 2018, when it rolled back its current program by increasing the number of doctors that it allowed to prescribe.
It was also one of the first federal agencies to phase in a new system for price gouging, which would allow insurers to charge higher prices for certain drugs.
The rules are scheduled to take effect on December 1, 2020, and the cost-of-care index will increase by an average of 5 percent every year from now until 2026.
CMS is also looking at ways to cut costs by providing incentives for manufacturers to produce better-quality drugs.
In 2017, the agency announced that, in addition to rebates and other rebates, it was launching a new program to help manufacturers make their drugs more affordable.
It also said it was looking at reducing the amount of time it takes for a drug to become prescription-only, a key part of lowering the cost.